Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls
Information source: University Hospital, Basel, Switzerland
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Non Alcoholic Fatty Liver Disease; Non Alcoholic Steatohepatitis
Intervention: Oral glucose tolerance test (Other)
Phase: N/A
Status: Completed
Sponsored by: University Hospital, Basel, Switzerland Official(s) and/or principal investigator(s):
Christoph Beglinger, MD, Principal Investigator, Affiliation: University Hospital Basel, Division of Gastroenterology and Hepatology
Summary
The incretin effect is impaired in patients with type 2 diabetes mellitus (T2DM), thus GLP-1
receptor agonists are used for the treatment of T2DM. Insulin resistance is a
pathophysiologic hallmark of non-alcoholic fatty liver disease (NAFLD). The incretin effect
in patients with NAFLD has not been studied. The aim of this study is to quantify GLP-1
secretion in response to oral glucose tolerance test (oGTT) in patients with NAFLD compared
to healthy controls. The results of this study will expand the knowledge of the
pathophysiology of NAFLD and serve as a rational for potential future treatment strategies.
Clinical Details
Official title: Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls
Study design: Observational Model: Case Control, Time Perspective: Prospective
Primary outcome: Glucagon-like Peptide 1 (GLP-1) secretion in response to oGTT
Secondary outcome: Insulin secretion and glucose curves in response to oGTT
Detailed description:
Primary endpoint: GLP-1 response to oral glucose Secondary endpoints: glucose and insulin
responses to oral glucose challenge
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Biopsy proven NAFLD or NASH
Exclusion Criteria:
- additional concomitants liver disease
- T2DM
- alcohol consumption >40g/d for male subjects and >20g/d for female subjects
Locations and Contacts
University Hospital Basel, Division of Gastroenterology and Hepatology, Basel, Switzerland
Additional Information
Starting date: January 2011
Last updated: August 24, 2012
|
